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Introduction and overview
Neisseria gonorrhoeae is a pathogen responsible for a number
of common and important disease syndromes (1). The organ-
ism is transmitted as a mucosal infection (2); humans are the
only definitive host. Indeed, it has been difficult, ifnot impossi-
ble, to establish a relevant infection in other animals, including
several primate species (3).
The correlation between gonococcal disease and the biol-
ogy of the organism has been studied extensively, and repre-
sents the purpose of this review. The most critical interactions
occur at the mucosal surface. The organism must attach to
epithelial cells and multiply. The organism must resist any in-
nate host defenses, as well as defenses that may have evolved
from prior infection. In male hosts, urethral infection with
most strains ofN. gonorrhoeae leads to symptomatic exudative
inflammatory response (1). However, infection ofthe endocer-
vix and other mucous membranes may be less obvious. In ad-
dition, some strains ofgonococci may remain in the urethra or
endocervix for long periods of time without producing symp-
toms (2). The precise reasons for "quiescent infection" are not
known, but such gonococcal strains generally have unique nu-
tritional requirements, extreme sensitivity to antibiotics, and
limited ability to activate the complement cascade or to gener-
ate neutrophil chemoattractant factors (2).
Gonococcal disease is important because it is a common
cause of salpingitis and female infertility (4). Under conditions
that are still not well understood, the organism may leave mu-
cous membranes (such as the endocervix) and infect the epithe-
lial cells of the fallopian tubes. Such migration requires pene-
tration of several immunological and nutritional barriers, and
a transport "carrier," since gonococci are not motile. Either
refluxed menstrual blood or attachment to spermatozoa may
aid in transit upstream against ciliated fallopian tube cells.
Gonococci less commonly produce bacteremia and sys-
temic disease. Disseminated gonococcal infection (DGI) in-
cludes infection ofthe skin, synovium, andjoints. Rarely, men-
ingitis or endocarditis may occur. To produce DGI, gonococci
must evade serum defenses and phagocyte surveillance.
In general, it is believed that a wide spectrum ofgonococcal
disease is possible because of multiple sophisticated adapta-
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tions of gonococci to selective pressures of the host. In this
article we will review our current understanding of the patho-
genesis of gonococcal infection at the mucosal surface. We
hope to convey exciting advances made possible through the
tools ofmolecular biology and more recent human experimen-
tation.
Gonococcal biology represents a model by which to under-
stand the effects of selective pressure in vivo and a myriad of
adaptive microbial strategies.
Gonococcal aim 1: establishing infection
Attachment (Fig. 1). The critical first step in establishing infec-
tion is attachment to host cells. Attachment ofN. gonorrhoeae
to epithelial cells has been studied extensively (5). Thirty years
ago Kellogg and his colleagues demonstrated that only gono-
cocci expressing pili (or a factor coexpressed with pili) were able
to establish infection in male human volunteers (6). This result
has recently been validated by Boslego and co-workers (P.
Hitchcock, personal communication). There are several other
nonpilus surface ligands for attachment, including opacity
(Opa)' proteins (7), a 37-kD protein that binds to certain cellu-
lar glycolipids (8). Multiple different adhesins may be required
to effect attachment to different types ofcells in diverse environ-
ments such as the urethra, cervix, fallopian tubes, and/or rec-
tum. Evidence for this conjecture comes from a variety of in
vitro studies, and from the very rapid selection in vivo of new
types of pili (9) and Opa proteins (10), before a specific im-
mune response. Both pili and Opa proteins are clearly impor-
tant in vivo; the importance of other adhesins remains to be
established.
Opa proteins are interesting from several points of view.
They are members ofa set ofas many as 11 closely related outer
membrane proteins, most of which confer an opaque appear-
ance to colonies. The colonial appearance is due to increased
adherence between gonococcal cells ( 11) which form multicel-
lular clumps (infectious units), potentially important in initia-
tion or maintenance ofgonococcal infection. Opa proteins also
appear to directly increase binding to some cells (7). Only a few
(or none) ofthe Opa proteins are expressed at one time. Varia-
tions or "switching" between different Opa proteins occurs at a
rate of about 1O-' per cell per generation. Control of Opa ex-
pression occurs by means of variations in length of a five-nu-
cleotide DNA repeat (CTCTT), within the signal sequence-en-
coding region of Opa genes; variations in numbers of the
(CTCTT). repeat result in translational frame shifts, and there-
1. Abbreviations used in this paper: CMP-NANA, cytidine monophos-
phate-N-acetylneuraminic acid; DGI, disseminated gonococcal infec-
tion; LF, lactoferrmn; LOS, lipooligosaccharide; Opa, opacity; Por, the
gonococcal porin; Rmp, reduction modifiable protein.
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Figure 1. Gonococcal attachment and adaptation. Gonococci dem-
onstrate constitutive expression of several outer membrane (OM)
structures during growth in vitro or in vivo, including porin protein
(Por), Protein III (reduction modifiable protein, Rmp), and the core
of LOS. Selective pressure through exposure to a mucosal environ-
ment may lead to substantive changes in the outer membrane, in-
cluding expression of new variants of pili (Pil), Protein II (opacity
protein, Opa), and LOS polysaccharides. Moreover, genes that are not
transcribed under usual growth conditions in vitro may be transcribed
in vivo, leading to formation of iron-repressible proteins for binding
transferrin (Thp) or lactoferrin (Lbp), or anaerobically expressed pro-
teins (Pan). Certain oxygen-regulated proteins (Pox) are expressed
only under aerobic conditions. It is possible that transferrin (TF)
and/or lactoferrin (LF) associated with epithelial cells facilitates at-
tachment of gonococci through Thp or Lbp. Growth of gonococci in
vivo leads to sialylation of LOS with host-derived cytidine mono-
phosphate-N-acetyl neuraminic acid (CMP-NANA). CM, cytoplasmic
membrane; PGN, peptidoglycan.
fore control of expression at the level of translation ( 12, 13). In
contrast, similarly high frequencies ofphase and antigenic vari-
ations of pili are due to recombination between incomplete,
variant "silent" pilin DNA cassettes and pilin structural genes,
and other transcriptional control mechanisms (14-16). High
frequency antigenic variation serves the dual purposes of
escape from immune surveillance, and provision of specific
ligands for different cell receptors.
Epithelial cell invasion. Several investigators have demon-
strated gonococcal invasion of epithelial cells in vitro (17, 18).
This is believed to represent parasite-directed endocytosis ( 19).
However, it is not clear whether epithelial invasion represents a
"normal" part of uncomplicated mucosal infection, or is im-
portant only to deeper, complicated infections, such as salpin-
gitis or the bacteremia-arthritis syndrome. Certain outer mem-
brane proteins may facilitate invasion of epithelial cells, in-
cluding outer membrane protein I (Por, the gonococcal porin)
(20), and some, but not all, Opa proteins (17, 18).
Adaptation (Fig. 1). Gonococci rapidly adapt to their mi-
croenvironment in vivo (9, 10), and similar adaptation can be
demonstrated quite easily in vitro (21-23). Variations in pili
and Opa are primarily genotypic (i.e., variations within the pil
or opa genes that alter their expression). Other important varia-
tions are primarily phenotypic (i.e., change in expression of
genes, without alteration in structure of the respective genes).
These occur principally in response to environmental stresses,
probably due to signal transduction mechanisms that alter ex-
pression of particular genes. Examples include increased syn-
thesis of iron-repressed outer membrane proteins (Frps), some
of which are necessary for specific gonococcal receptors for
binding human iron transport proteins such as transferrin and
lactoferrin (2 1); synthesis ofouter membrane proteins that nor-
mally are repressed by oxygen (Pan; 22); synthesis ofgrowth-re-
lated stress proteins (GSPs; 24), and synthesis of proteins
evoked by contact with epithelial cells (25). Compelling evi-
dence for expression in vivo ofsome ofthese stress proteins can
be derived from experiments in which serum from subjects
with uncomplicated gonococcal infection, pelvic inflamma-
tory disease, and/or disseminated gonococcal infection demon-
strate antibodies to one or more of these proteins (reviewed in
reference 26). These data indicate that gonococci sometimes
grow in vivo under conditions of relative iron deprivation and
anaerobiosis.
It is possible that different outer membrane proteins are
formed in different sites of disease, such as the urethra, endo-
cervix, and fallopian tube, although this has not been well stud-
ied. Recognition that in vitro phenotypes may be considerably
different than those expressed in vivo has critical implications
for vaccine development.
Indeed, these observations are so important that they have
lead to fairly extensive experimentation with human volunteer
subjects (9, 10, and unpublished data, A. Jerse, J. Cannon, and
M. S. Cohen). Particular Opa proteins (10) or an increased
number of Opa proteins (unpublished data) appear to be se-
lected in vivo. Variations of gonococcal lipooligosaccharide
(LOS) also seem to be important (27). Schneider and co-
workers studied LOS variation in volunteer subjects challenged
with intraurethral N. gonorrhoeae (27), and demonstrated an
evolution of LOS phenotype during the course of infection.
This evolution in part reflects sialyiation of LOS by cytidine
monophosphate-N-acetylneuraminic acid (CMP-NANA), a
change that provides gonococci with an unstable form ofserum
resistance that may be required for infection (see below). It also
reflects high frequency (- 10-) variation in expression of cer-
tain core sugars in LOS (23). The mechanisms for variable
expression of LOS core sugars are unknown.
A schema ofgonococcal adaptations that aid in establishing
infection is provided in Fig. 1. Adherence ligands such as pili
and one or more Opa proteins allow initial attachment of the
bacteria to epithelial cells. Selective pressure leads to expres-
sion of a variety of other proteins potentially important for
more effective attachment, nutritional support, cellular inva-
sion, replication, and perhaps, most importantly, evasion of
human host defenses.
Gonocococcol aim 2: evasion ofmucosal defenses
Inflammation associated with gonococcal infection represents
a combination of failed host defense mechanisms and the di-
rect cytotoxicity ofthe organism. Mucosal secretions contain a
variety of nonspecific host defenses including lysozyme and
iron binding proteins such as transferrin and lactoferrin (28).
Most gonococci are well adapted to use these nonspecific de-
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fenses to their own advantage. Specific host defenses are be-
lieved to play a more critical role in the inflammatory biology
ofgonococcal infection. These include the interaction ofgono-
cocci with serum and antibodies, neutrophilic phagocytes, and
the cells and cytokines required for cell-mediated immunity.
Gonococci, serum, and humoral immunity (Fig. 2). Human
serum, even in subjects who have not had prior infection with
N. gonorrhoeae, contains a variety of antibodies bactericidal
for many gonococci (29-31, and reviewed in 26). These anti-
bodies are generally directed against one or more components
ofLOS, but they may also be directed against a variety ofother
antigens (29-31). Subjects with priorgonococcal infection dem-
onstrate antibodies to multiple antigens, both in serum and
mucosal secretions (29-31).
How do gonococci resist serum-mediated death? Twenty
years of study have lead to an exciting but highly complex
answer to this question. After growth in vitro, some gonococci
are phenotypically sensitive to complement-mediated killing
by human sera, whereas others are stably resistant to the same
sera. It now seems likely, however, that most gonococci are
phenotypically resistant to killing by normal human serum in
vivo. Genetically determined stable serum resistance is proba-
bly due to the particular type of Por protein expressed (32);
these organisms are often the cause ofdisseminated gonococcal
disease. Other strains that become sensitive to serum only after
growth in vitro rapidly acquire phenotypic serum resistance
through exposure to human red and white blood cells (33),
serum (34), or growth in vivo (27, 35). Phenotypic conversion
to serum resistance in vivo is due to sialylation of LOS by
gonococcal use of host-derived CMP-NANA (27, 35). CMP-
NANA is the substrate used by mammalian cells for sialylation
Figure 2. Gonococci resist serum-medicated defenses. Secretory IgA
may block gonococcal attachment, but a gonococcal protease de-
grades IgA,. IgG and IgM directed against porin (Por) and/or LOS
lead to complement-mediated gonococcal lysis. However, blocking
antibodies directed against Protein III (Rmp) or sialylation of LOS
may inhibit serum killing, most likely by interfering with complement
fixation (37, 38). IgG and IgM could also opsonize gonococci and
facilitate their uptake by phagocytes. Sialylation ofLOS may interfere
with opsonization (40).
of glycolipids and glycosphingolipids. During gonococcal in-
fection, LOS epitopes capable of sialylation may be preferen-
tially expressed (27, 36), and most or all gonococci produce the
enzyme sialyltransferase required to effect this modification to
LOS structure.
Another distinct mechanism for phenotypic serum resis-
tance is binding ofblocking antibodies to outer membrane pro-
tein III (Rmp) that interfere with natural or acquired bacteri-
cidal antibodies directed against outer membrane Por or LOS
(37, 38). Gonococcal Rmp is similar in structure to Escherichia
coli ompA (37) and to analagous proteins in other Neisseriae,
including meningococci, and it is likely that antibodies formed
to other bacteria in normal hosts may be important in the gene-
sis of cross-reactive anti-gonococcal blocking antibodies.
Blocking antibodies have been demonstrated in sex workers
with repeated gonococcal infection (39), supporting the idea
that formation of blocking antibody may enhance susceptibil-
ity to mucosal infection.
The multiplicity of mechanisms employed by gonococci to
protect against damage by antibody and complement suggest
the importance ofthis defense. The mechanisms for protection
against complement involve inability of the terminal mem-
brane attack complex (5b-9) to insert into the bacterial mem-
brane in the configuration required for killing (reviewed in 38).
Serum sensitive or resistant gonococci bind similar concentra-
tions ofC7 and C9 molecules from normal human serum (38).
However, the binding patterns are different between serum re-
sistant and sensitive organisms (38). Sialylation may limit or
alter complement binding, thereby interfering with killing of
gonococci by LOS antibodies, and/or antibodies directed
against Por, as well as complement-dependent phagocytosis
(see below, 40). Complement components could also play a
direct role in injury to host cells, but there is no evidence for
this in gonococcal infection.
Interaction between gonococci and serum leads to forma-
tion ofchemoattractant factors that are expected to evoke neu-
trophilic inflammation. Densen and co-workers (41) showed
that serum-sensitive gonococci (which are the usual cause of
symptomatic urethral infection) generate complement-derived
chemoattractants at a faster rate and in higher concentration
than phenotypically stable serum-resistant isolates. Stable
serum-resistant gonococcal isolates bind iC3b in vivo and in
vitro better than serum-sensitive strains, allowing inactivation
of C3 cleavage products and preventing full expression of C5
convertase required to generate the chemotaxin C5a (42). Sial-
ylation of LOS does not appear to effect C3b cleavage (42).
Genotypically stable, serum-resistant isolates are associated
with asymptomatic male urethral infection (43), perhaps due
to their relative inability to generate chemotaxins and a local
purulent response (41-43).
Mucosal antibodies and secretory IgA. IgG, IgM, and IgA
antibodies directed against gonococcal antigens have been de-
tected at mucosal surfaces (29, and reviewed in 26). IgA is
made daily in concentrations higher than other antibody
classes, and two unique secretory subclasses (SIgA, and 2) are
generated by mucosal lymphocytes (reviewed in 28). The pre-
cise function ofSIgA is not known, but it is clearly not opsonic.
Tramont and co-workers demonstrated that both IgG and IgA
can prevent attachment of gonococci to buccal epithelial cells
(44). However, gonococci (and other pathogenic Neisseria)
form an IgA, protease that cleaves the hinge region of the IgA
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dimer. The ability of SIgA to prevent gonococcal infection in
vivo has not been demonstrated.
Phagocytic cells (Fig. 3)
Gonococci are pyogenic bacteria. Although the prevalence of
asymptomatic or oligosymptomatic gonococcal strains helps to
explain the persistence ofthis disease in humans (1), the major-
ity of subjects with acute gonococcal infection develop a frank
and painful purulent exudate (1, 2). Granulocytes evoked in
this setting probably are responsible for the majority ofmuco-
sal damage observed. Interactions between N. gonorrhoeae and
phagocytic cells have been studied extensively. Several impor-
tant questions have not been answered, including whether
phagocytes are capable ofkilling all gonococci in a small inocu-
lum, and whether gonococcal adaptation is required for sur-















Figure 3. Gonococci and phagocytes. (A) Phagocytes generate O-,
H202, and other reactive oxygen intermediates, which (in concert
with microbicidal proteins) might be expected to kill gonococci.
However, gonococcal adaptation (Fig. 3, a and b) is likely an impor-
tant part of resistance in vivo. Gonococci exposed to neutrophils
demonstrate an increase in catalase, which facilitates resistance to
neutrophils. Gonococcal use of neutrophil L(+)-lactate allows°2
consumption adequate to inhibit neutrophil generation of°2, and
could ultimately lead to an anaerobic environment. Neutrophil-de-
rived nitric oxide could replace 02 as a terminal electron acceptor,
required for bacterial growth. C, cytoplasm; CM, cytoplasmic mem-
brane; PGN, peptidoglycan; OM, outer membrane; Pil, pilin; Por,
porin; Opa, opacity proteins; G-GPDH, glucose 6-phosphate dehy-
drogenase; LDH, lactate dehydrogenase; NO, nitric oxide. (B) Several
other mechanisms accounting for the survival of gonococci during
neutrophil attack have been proposed. Inadequate attachment of
Opa- gonococci and/or gonococci expressing variant Opa proteins
could lead to extracellular survival; pili and/or other gonococcal
"factors" could also inhibit phagocytosis directly. Formation of a
unique 20-kD protein after phagocytosis could permit intracellular
survival. Translocation of gonococcal Por protein to the phagocyte
could inhibit neutrophil deregulation, also leading to intracellular
survival of gonococci.
Phagocytes employ different microbicidal mechanisms for
aerobic and anaerobic conditions. Both aerobic and anaerobic
organisms may be recovered from vaginal secretions (45) and
the male urethra (46). Gonococci are facultative anaerobes
(47), and Clark and co-workers demonstrated serum immune
responses during urethral infection to Pan (anaerobic) gonococ-
cal proteins (48). It can be assumed that in some phase ofgono-
coccal infection the mucosa is aerobic, ifonly at the male ante-
rior urethra. During this time, gonococci would use oxygen as a
terminal electron acceptor and mucosal substrates for growth.
Iron could be provided by lactoferrin, transferrin, or other mu-
cosal iron-binding proteins. Gonococci preferentially use L(+)-
lactate for growth rather than glucose (49). Lactate is found in
serum and is generated by phagocytes during aerobic glycolysis
evoked by phagocytosis (50). The use of L(+)-lactate by gono-
cocci is potentially important because of phenotypic changes
that may occur through the use of this substrate (49), and be-
cause gonococci using L(+)-lactate demonstrate markedly ac-
celerated competition for molecular oxygen (50). Indeed,
through competition for molecular oxygen gonococci may pre-
vent neutrophil generation of oxidants (see below, and Fig. 3),
and help to generate a strict anaerobic environment, thereby
potentiating growth of obligate anaerobes (e.g., Bacteroides
species) recovered from the fallopian tubes ofwomen with sal-
pingitis (4). Gonococci adapt to anaerobic conditions through
the use of nitrite as a terminal electron acceptor (22, 47, 48).
Nitrite can be recovered from several tissue sites and is gener-
ated by neutrophils and macrophages during phagocytosis (51).
Phagocytosis. Phagocytic cells unquestionably come into
intimate contact with gonococci. Examination of urethral neu-
trophilic exudates demonstrates both intracellular and extra-
cellular gonococci (35). By what mechanisms do gonococci at-
tach to neutrophils? Under what circumstances are neutrophils
able to ingest gonococci? A variety of antibodies that react with
gonococcal outer membrane proteins have been identified.
Some of these antibodies appear to enhance the association of
gonococci with neutrophils (52, reviewed in 53). However,
most studies fail to differentiate between antibody-enhanced
cell association and phagocytosis. Interpretation of the role of
"opsonic" antibodies is made more complicated because it has
become clear that one or more gonococcal outer membrane
proteins also mediate association with leukocytes. Swanson
demonstrated that some Opa+ colonies adhere to granulocytes
(54), and using other techniques these results have been veri-
fied in several laboratories (55, 56). It has also been demon-
strated that certain Opa+ gonococci are killed by human neutro-
phils in vitro, whereas Opa- organisms survive (56). These re-
sults imply that Opa- strains might be selected in vivo.
However, only Opa' gonococci are recovered from human vol-
unteers inoculated with Opa- organisms (10, A. Jerse, J. Can-
non, M. Cohen, unpublished data), which suggests that expres-
sion of Opa proteins is required for establishment of infection,
possibly because Opa proteins enhance attachment to and/or
penetration of mucosal epithelial cells (17, 18). Further com-
plicating interpretation of results are the ideas that (a) gono-
cocci express one or more antiphagocytic factors, perhaps in-
cluding pili (57); and (b) sialylation of LOS may effect opsoni-
zation (40) and/or the function of Opa proteins.
Oxygen-dependent events. The enzymatic system that al-
lows phagocytes to reduce molecular oxygen to superoxide an-
ion has been reviewed in detail (58), as have the various oxi-
dants formed by this system (59). Gonococci are sensitive to
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superoxide and hydrogen peroxide in vitro (60, 61). Gonococci
generate high concentrations of catalase (62, 63), which cata-
lyzes formation of 02 and H20 from H202, but no superoxide
dismutase (62-64). A catalase-deficient mutant ofgonococci is
significantly more sensitive to neutrophils than catalase-replete
strains (63). In addition, briefexposure ofgonococci to phago-
cytizing neutrophils or exogenous hydrogen peroxide leads to a
significant increase in catalase concentration, as well as resis-
tance to neutrophil attack (63). It seems possible that early
upregulation of catalase production may help gonococci sur-
vive attack by neutrophils in an aerobic environment.
An additional aspect ofthe mucosal biology of neutrophils
involves the iron-binding protein lactoferrin (LF). Most gono-
cocci express receptors for binding LF, and can use LF as a sole
source of iron (21). During phagocytosis, neutrophils secrete
LF into the supernatant, which paradoxically may stimulate
growth ofgonococci by providing a usable source ofFe3", even
at very low levels (i.e., 2%) of iron saturation (65). Fe3" bound
to neutrophil LF will not catalyze the formation of hydroxyl
radical, which would be formed through the interaction of02
and H202 in the presence of Fe3" (66). Since hydroxyl radical
degrades mucus proteins (67) and damages normal epithelial
cells, neutrophil secretion of LF may help to prevent tissue
damage.
Anaerobic conditions. Gonococci can also be killed by neu-
trophils under anaerobic conditions. Proteins that might con-
tribute to such killing have been described in detail, and in-
clude cationic proteins of molecular weight of 37,000, 57,000,
and cathepsin G (68). Small molecular weight defensins do not
appear to play an important role in gonococcal killing.
Surviving neutrophil attack (Fig. 3 B). Gonococci clearly
survive exposure to neutrophils in vivo. As discussed above,
lack of association with neutrophils of Opa- gonococci, or se-
lected Opa variants, may allow bacterial survival. Upregulation
of gonococcal catalase production helps to defend against oxi-
dative killing (63), as does aggressive competition for molecu-
lar 02 (50). Low level penicillin-resistant isolates containing
altered penicillin-binding protein 2 demonstrate increased resis-
tance in vitro to killing by cathepsin G (69). A 20-kD gonococ-
cal outer membrane protein appears to inhibit neutrophil in-
tracellular killing (70), and other work suggests a similar role
for the gonococcal Por protein (71). In vitro, Por can transfer
into mammalian cell lipid bilayers (72); purified Por protein
can inhibit neutrophil degranulation, perhaps through interfer-
ence with neutrophil signal transduction (73). However, all
mechanisms to explain gonococcal survival during neutrophil
attack are speculative; convincing evidence for the importance
of these gonococcal defenses in vivo is lacking.
Cell-mediated immunity and tissue injury
An important aspect of the inflammatory response is the con-
tribution of cell-mediated immunity, as characterized by an
interaction between lymphocytes and macrophages, and the
generation of a variety oflymphokines and monokines. A sys-
temic lymphocyte response during gonococcal infection has
been demonstrated, b'ut does not confer immunity (74). Hu-
man peripheral blood lymphocytes demonstrate both anti-
body-dependent cytotoxicity and natural killing activity di-
rected against N. gonorrhoeae (74, 75). Similar activity has
been demonstrated in cells isolated from human fallopian
tubes (74, 75). Using human fallopian tubes in tissue culture,
McGee and co-workers showed that gonococci cause remark-
able ciliary inhibition and sloughing, especially compared with
nonpathogenic Neisseriae (19, 76); gonococcal LOS is at least
in part responsible for cytotoxicity observed (19, 75, 76).
Gonococcal antigens are processed by fallopian tube lym-
phocytes (74), leading to increased secretion of IgA (77) and a
variety of cytokines (78). McGee and co-workers reported for-
mation of tumor necrosis factor (TNF) in fallopian tubes,
which could also be induced by gonococcal LOS (79). TNF
alone may be sufficient to produce the fallopian tube injury
caused by gonococcal LOS (79). These results imply that TNF
and other cytokines mediate the cytotoxicity ofgonococcal in-
fection. These observations have important implications for
our understanding of the pathogenesis of pelvic inflammatory
disease (PID), and for possible pharmacologic strategies to
limit fallopian tube damage during gonococcal infection.
Mucosal inflammation and vaccine development
Most studies of N. gonorrhoeae are geared toward a better un-
derstanding of the pathogenesis of the disease and/or vaccine
development. We have summarized only a small portion ofan
explosion of information about this organism. Successful vac-
cine development will require one or more of the following
components: (a) generation of serum or mucosal antibodies
that either block attachment, facilitate complement-mediated
lysis of the organism, enhance neutrophilic phagocytosis and/
or microbial killing, or mediate antibody dependent cytotoxic-
ity; and (b) evocation of cell mediated defenses that prevent
infection or ameliorate fallopian tube damage.
Vaccines using pili (80) and Por (personal communication,
E. W. Hook, III) failed to confer clinically useful immunity to
gonococcal infection. In the case of the pilus vaccine, signifi-
cant immunity was noted for the homologous strain, but not
for heterologous strains expressing different antigenic types of
pili (81). Studies with Por vaccine probably were complicated
by contamination with blocking antigen (Rmp) that may have
interfered with vaccine efficacy (37). Since these studies were
performed in the early 1980s, before much was known about
either gonococcal phenotypic variation in vivo or about the
structure and function ofa number ofother surface antigens, it
is possible that renewed attempts to make a vaccine against
relatively stable surface antigens will prove successful. For in-
stance, vaccination with Por purified from recombinant E. coli
(82) or from gonococcal mutants lacking Rmp (83) should cir-
cumvent the problem of blocking antibodies (C. Elkins and
P. F. Sparling, unpublished data). Existing data are encourag-
ing in certain respects. Patients developing mucosal infection
with gonococci expressing a particular Por serovar may be less
likely to develop recurrent infection with strains expressing the
same Por (84), suggesting partial mucosal immunity based on
Por epitopes. Since Por is not subject to high frequency anti-
genic variations, identification of conserved immunogenic do-
mains on Por may lead to vaccines based on Por. Other gono-
coccal surface antigens including some stress proteins are at
least partially conserved, and may represent viable vaccine
candidates.
Each of these advances represents a clear outgrowth ofbasic
and applied research with N. gonorrhoeae. Development of a
vaccine, coupled with educational strategies that lead to reduc-
tions in risky sexual behaviors (85), could dramatically reduce
the consequences ofgonococcal infection. Although gonococci
are masters of deceit and immune evasion (Table I), develop-
ment of a vaccine remains an attractive goal.
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Table I. Strategies Employed by Gonococci to Escape Immune
Surveillance and/or to Adapt Rapidly to Particular
Environmental Niches
1. High frequency (l0-3) phase and antigenic variation of surface
antigens
a. Pili
b. Opacity (Opa) proteins
c. LOS core sugars
2. Gene regulation by environmental factors
a. Iron-repressible proteins (Frps)
b. Anaerobically-expressed proteins (Pans)
c. Oxygen-expressed proteins (Poxs)
d. Other stress proteins
e. Catalase
f. Lactate dehydrogenase (?)
3. Molecular masking
a. Sialylation of LOS
4. Binding of non-complement fixing "blocking" antibodies
a. Rmp (protein III)
5. Inactivation of mucosal antibodies
a. IgA 1 protease secretion
6. Subversion of nonspecific host defenses
a. Specific receptors for transferrin, lactoferrin
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